Abstract
As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age ≥15 years at diagnosis), 164 as infants (0–1 year), 413 as younger children (2–11 years), and 161 as older children (12–14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 %) was significantly lower than that of the other three groups (P = 0.019): 68.7 % for infants, 73.2 % for younger children, and 75.5 % for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 %) than that in infants (14.8 %), younger children (10.2 %), and older children (13.8 %). Multivariate analysis showed age ≥15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 318-326 |
| Number of pages | 9 |
| Journal | International Journal of Hematology |
| Volume | 102 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jul 1 2015 |
Fingerprint
Keywords
- Acute myeloid leukemia
- Adolescents
- Children
ASJC Scopus subject areas
- Hematology
Cite this
Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. / Tomizawa, Daisuke; Watanabe, Tomoyuki; Hanada, Ryoji; Horibe, Keizo; Horikoshi, Yasuo; Iwamoto, Shotaro; Kinoshita, Akitoshi; Moritake, Hiroshi; Nakayama, Hideki; Shimada, Akira; Taga, Takashi; Takahashi, Hiroyuki; Tawa, Akio; Terui, Kiminori; Hori, Hiroki; Kawano, Yoshifumi; Kikuta, Atsushi; Manabe, Atsushi; Adachi, Souichi.
In: International Journal of Hematology, Vol. 102, No. 3, 01.07.2015, p. 318-326.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols
AU - Tomizawa, Daisuke
AU - Watanabe, Tomoyuki
AU - Hanada, Ryoji
AU - Horibe, Keizo
AU - Horikoshi, Yasuo
AU - Iwamoto, Shotaro
AU - Kinoshita, Akitoshi
AU - Moritake, Hiroshi
AU - Nakayama, Hideki
AU - Shimada, Akira
AU - Taga, Takashi
AU - Takahashi, Hiroyuki
AU - Tawa, Akio
AU - Terui, Kiminori
AU - Hori, Hiroki
AU - Kawano, Yoshifumi
AU - Kikuta, Atsushi
AU - Manabe, Atsushi
AU - Adachi, Souichi
PY - 2015/7/1
Y1 - 2015/7/1
N2 - As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age ≥15 years at diagnosis), 164 as infants (0–1 year), 413 as younger children (2–11 years), and 161 as older children (12–14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 %) was significantly lower than that of the other three groups (P = 0.019): 68.7 % for infants, 73.2 % for younger children, and 75.5 % for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 %) than that in infants (14.8 %), younger children (10.2 %), and older children (13.8 %). Multivariate analysis showed age ≥15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.
AB - As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age ≥15 years at diagnosis), 164 as infants (0–1 year), 413 as younger children (2–11 years), and 161 as older children (12–14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 %) was significantly lower than that of the other three groups (P = 0.019): 68.7 % for infants, 73.2 % for younger children, and 75.5 % for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 %) than that in infants (14.8 %), younger children (10.2 %), and older children (13.8 %). Multivariate analysis showed age ≥15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.
KW - Acute myeloid leukemia
KW - Adolescents
KW - Children
UR - http://www.scopus.com/inward/record.url?scp=84941259016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941259016&partnerID=8YFLogxK
U2 - 10.1007/s12185-015-1825-x
DO - 10.1007/s12185-015-1825-x
M3 - Article
VL - 102
SP - 318
EP - 326
JO - International Journal of Hematology
JF - International Journal of Hematology
SN - 0925-5710
IS - 3
ER -